Browsing Tag
oncology drug development
11 posts
Could oral elraglusib emerge as a combination backbone for RAS-targeted cancer therapies?
Actuate Therapeutics, Inc. is advancing oral elraglusib to target resistance biology in cancer. Discover what this means for oncology markets.
Can KST-6051 unlock broader KRAS cancer treatment beyond G12C inhibitors
KST-6051 enters Phase 1 with AbbVie Inc. backing. Discover how pan-KRAS inhibitors could expand treatment across KRAS-driven cancers.
How oral Targeted Glue degraders could change dosing paradigms in cancer treatment
Discover how oral Targeted Glue degraders could transform cancer dosing strategies and reshape oncology treatment models. Read the full analysis.
Could a proenzyme therapy disrupt chemotherapy’s dominance in pancreatic cancer treatment?
Can Propanc Biopharma’s PRP therapy reshape pancreatic cancer treatment? Discover what the biotech’s metastasis-focused strategy could mean for oncology.
Is Merck & Co., Inc. embedding artificial intelligence at the core of its oncology strategy through Tempus AI integration?
Merck expands its Tempus AI collaboration to embed artificial intelligence into oncology research. What this means for MRK, TEM, and precision medicine.
How a proenzyme-based approach from Propanc Biopharma tests the limits of current solid tumor paradigms
Can a proenzyme therapy reshape solid tumor treatment models? Explore what Propanc Biopharma’s PRP strategy signals for oncology markets.
From lab validation to clinical execution: Adaptin Bio advances a novel glioblastoma therapy toward trials
Find out how Adaptin Bio is moving a novel glioblastoma therapy from lab validation into early clinical execution and what this step means for brain cancer research.
Independent cardiac safety review finds no cardiotoxicity for Moleculin’s annamycin, removing a major anthracycline overhang
Independent reviewers found no cardiotoxicity for Moleculin’s annamycin in 90 subjects. See how this milestone de-risks the oncology pipeline.
Why Immunome’s Phase 3 varegacestat data could reshape the desmoid tumor treatment market
Immunome is set to release Phase 3 varegacestat data that could redefine its oncology strategy and valuation. Read what this catalyst really means.
Schrödinger earns FDA Fast Track for SGR-1505 in Waldenström macroglobulinemia amid rising therapeutic demand
Schrödinger’s SGR-1505 receives FDA Fast Track designation for Waldenström macroglobulinemia, highlighting a novel MALT1-targeted approach.